Agenus (NASDAQ:AGEN) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Agenus (NASDAQ:AGEN) in a research report report published on Tuesday, Benzinga reports. They currently have a $40.00 target price on the biotechnology company’s stock.

Several other equities research analysts have also weighed in on AGEN. B. Riley reduced their price objective on Agenus from $120.00 to $100.00 and set a buy rating for the company in a research note on Monday, March 18th. StockNews.com started coverage on Agenus in a research report on Wednesday, April 17th. They issued a hold rating for the company.

Agenus Trading Up 2.2 %

Shares of NASDAQ AGEN opened at $11.72 on Tuesday. Agenus has a twelve month low of $4.78 and a twelve month high of $42.60. The firm has a 50-day moving average of $10.67 and a two-hundred day moving average of $13.22. The company has a market capitalization of $237.74 million, a price-to-earnings ratio of -0.83 and a beta of 1.25.

Agenus (NASDAQ:AGEN) last released its earnings results on Thursday, March 14th. The biotechnology company reported ($2.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($2.20). The company had revenue of $83.80 million for the quarter, compared to analyst estimates of $54.21 million. As a group, research analysts predict that Agenus will post -8.21 earnings per share for the current year.

Insider Activity at Agenus

In other news, insider Garo H. Armen acquired 25,000 shares of the stock in a transaction on Thursday, February 15th. The shares were purchased at an average cost of $13.00 per share, for a total transaction of $325,000.00. Following the transaction, the insider now owns 31,298 shares in the company, valued at approximately $406,874. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 4.80% of the stock is owned by insiders.

Institutional Trading of Agenus

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in Agenus by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company’s stock worth $30,440,000 after purchasing an additional 432,202 shares during the last quarter. Braidwell LP grew its stake in shares of Agenus by 34.3% in the 3rd quarter. Braidwell LP now owns 6,307,030 shares of the biotechnology company’s stock valued at $7,127,000 after buying an additional 1,609,100 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Agenus by 3,008.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after buying an additional 2,232,064 shares during the last quarter. Readystate Asset Management LP raised its position in Agenus by 14.3% during the fourth quarter. Readystate Asset Management LP now owns 2,016,783 shares of the biotechnology company’s stock valued at $1,670,000 after acquiring an additional 252,124 shares in the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in Agenus by 16.9% in the third quarter. Rafferty Asset Management LLC now owns 1,680,974 shares of the biotechnology company’s stock valued at $1,900,000 after acquiring an additional 243,023 shares during the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.